Welcome to our dedicated page for Rezolute news (Ticker: RZLT), a resource for investors and traders seeking the latest updates and insights on Rezolute stock.
Rezolute, Inc. (NASDAQ: RZLT) is a clinical-stage biopharmaceutical company focused on developing innovative drug therapies aimed at improving the lives of patients suffering from metabolic and orphan diseases. The company's core mission is to address significant unmet medical needs through a diversified pipeline of cutting-edge treatments.
One of Rezolute's most promising candidates is RZ358, currently in Phase 2 clinical trials. RZ358 is a monoclonal antibody designed for the treatment of congenital hyperinsulinism (CHI), an ultra-orphan condition. This drug has shown significant promise in improving hypoglycemia across multiple endpoints, with plans to report topline data by mid-second quarter 2024.
Another key asset is AB101, a once-weekly injectable basal insulin presently in Phase 1 trials. AB101 has the potential to revolutionize diabetes management by reducing the therapeutic burden on patients and enhancing compliance. Additionally, Rezolute is developing RZ402, a plasma kallikrein inhibitor targeting diabetic macular edema (DME), with plans to file an IND in the latter half of 2018.
Rezolute applies proprietary formulation and manufacturing capabilities to well-characterized molecules, creating differentiated, patent-protected therapies. This approach not only improves existing standards of care but also offers significant commercial potential. The company has received multiple designations for its products, including Orphan Drug Designation for RZ358 in the U.S. and Europe, and PRIME designation by the European Medicines Agency.
Recent developments include plans to complete enrollment for ongoing studies by the end of 2024 and to report topline results by mid-year 2025. These milestones underline Rezolute's commitment to advancing its clinical programs and bringing transformative therapies to market.
For more detailed information and latest updates, visit the company's official website at www.rezolutebio.com.
Rezolute has secured a $30 million debt financing agreement with SLR Capital Partners to enhance its funding capabilities for advancing targeted therapies for rare and metabolic diseases. The initial $15 million was funded upon closing, with an interest-only period lasting 24 months. The remaining funds may be accessed upon meeting specific milestones. CEO Nevan Elam highlighted that this facility provides non-dilutive operational flexibility as they progress their pipeline, including lead candidate RZ358, currently in Phase 2b development.
Rezolute, Inc. (RZLT) announced positive results from its Phase 2a study of RZ358 for post-gastric bypass hypoglycemia at ENDO 2021. The study demonstrated a significant over 50% improvement in hypoglycemia, achieving near-normal glucose levels. RZ358 was safe, well-tolerated, and did not induce hyperglycemia. The pharmacokinetic model supports the potential effectiveness of RZ358 in future trials, including those for congenital hyperinsulinism. Rezolute is advancing RZ358, which has received Orphan Drug Designation in multiple regions.
Rezolute, Inc. (Nasdaq: RZLT) has appointed Dr. Vlad Hogenhuis and Dr. Nerissa C. Kreher to its Board of Directors as the company advances its lead candidate, RZ358, through late-stage clinical trials for congenital hyperinsulinism.
Dr. Hogenhuis brings extensive experience in rare diseases and has held significant roles in global pharmaceutical companies. Dr. Kreher has a robust background in clinical development within the biotech sector. Their expertise is expected to enhance Rezolute's growth as it continues to develop therapies for rare metabolic disorders.
Rezolute, Inc. (Nasdaq: RZLT) announced CEO Nevan Charles Elam will present at two upcoming virtual investor conferences. The first is the Cowen 41st Annual Health Care Conference on March 3, 2021, at 4:00 p.m. ET. The second is the Oppenheimer 31st Annual Healthcare Conference on March 16, 2021, at 2:30 p.m. ET. Webcasts will be accessible on the conference portals. Rezolute is advancing therapies for rare diseases, focusing on RZ358 for congenital hyperinsulinism and RZ402 for diabetic macular edema. For details, visit their website.
Rezolute, Inc. (RZLT) reported a net loss of $7.1 million, or $0.88 per share, for Q2 FY2021, an increase from a loss of $6.7 million, or $1.14 per share, in Q2 FY2020. Cash and cash equivalents were $37.0 million as of December 31, 2020, bolstered by $37.5 million from an October 2020 financing round. The ongoing Phase 2b study of RZ358 for congenital hyperinsulinism is enrolling patients, with results expected in H2 2021. Additionally, Rezolute initiated a Phase 1 study of RZ402 in January 2021, targeting diabetic macular edema, with completion anticipated in H1 2021.
Rezolute (RZLT) has initiated dosing in a Phase 1 clinical trial for RZ402, an oral plasma kallikrein inhibitor targeting diabetic macular edema (DME). This trial (RZ402-101) aims to assess safety, tolerability, and pharmacokinetics in healthy adults, with completion expected in early 2021. This milestone expands Rezolute's pipeline, reinforcing its commitment to novel therapies for serious metabolic diseases. RZ402's oral administration could optimize treatment outcomes for DME, where current therapies face compliance challenges.
Rezolute, Inc. (Nasdaq:RZLT) announced the appointment of IssuerDirect as its new registrar, transfer agent, and shareholder support provider, replacing VStock Transfer, LLC. This transition requires no action from shareholders. Rezolute is focused on developing therapies for rare and metabolic diseases, with its lead asset, RZ358, in Phase 2b for treating congenital hyperinsulinism. Another pipeline drug, RZ402, is an oral plasma kallikrein inhibitor, set to enter clinical development for diabetic macular edema.
Rezolute, Inc. (Nasdaq:RZLT) announced the FDA's clearance of an Investigational New Drug (IND) application for RZ402, an orally available plasma kallikrein inhibitor aimed at treating diabetic macular edema (DME). A Phase 1 clinical study is expected to start in Q1 2021. RZ402 has demonstrated over 80% reduction in retinal inflammation and vascular leakage in preclinical rodent models, with a favorable safety profile. This drug aims to address current treatment limitations by providing an effective oral alternative for DME, enhancing patient compliance.
Rezolute, Inc. (Nasdaq:RZLT) will present a corporate overview at the Piper Sandler 32nd Annual Virtual Healthcare Conference from November 23 to December 3, 2020. CEO Nevan Charles Elam will lead the presentation, accessible through the conference's recording library. Additionally, Rezolute will conduct 1x1 meetings, available upon request. The company focuses on developing targeted therapies for rare and metabolic diseases, with its lead asset RZ358 in Phase 2b for congenital hyperinsulinism. RZ402 is also set to enter clinical trials for diabetic macular edema.
Rezolute, Inc. (OCTQB:RZLT) has announced a $41 million private placement financing led by CAM Capital, with participation from other notable investors. The funds will advance RZ358 for congenital hyperinsulinism, initiate a Phase 1 study for RZ402 targeting diabetic macular edema, and cover general corporate purposes, including a potential Nasdaq listing. The company plans to issue approximately 124 million shares at $0.33 each, accompanied by warrants. A reverse stock split of 1:50 is also anticipated to meet Nasdaq requirements.
FAQ
What is the current stock price of Rezolute (RZLT)?
What is the market cap of Rezolute (RZLT)?
What does Rezolute, Inc. specialize in?
What is RZ358?
What stage is AB101 in?
What is RZ402?
What designations has RZ358 received?
When will Rezolute report topline data for their clinical trials?
What makes Rezolute's therapies unique?
What is the goal of AB101?
What recent developments has Rezolute announced?
Where can I find more information about Rezolute, Inc.?
